T regulatory cells and the control of alloimmunity: From characterisation to clinical application

Current Opinion in Immunology

Volumn 22, Issue 5, 2010, Pages 662-668

  Wieckiewicz, Joanna ^a   Goto, Ryoichi ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ALLOIMMUNITY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL LINEAGE; CELL THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA METHYLATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; VIRUS IMMUNITY;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL TRIALS AS TOPIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; MICE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 78049267160     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.08.011     Document Type: Review

References (46)

1. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
2. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
3. Karim M., Kingsley C.I., Bushell A.R., Sawitzki B.S., Wood K.J. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004, 172:923-928.
4. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., Shevach E.M. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010, 184:3433-3441.
5. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
6. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
7. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
8. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8:277-284.
9. Lal G., Bromberg J.S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009, 114:3727-3735.
10. Lal G., Zhang N., van der Touw W., Ding Y., Ju W., Bottinger E.P., Reid S.P., Levy D.E., Bromberg J.S. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009, 182:259-273.
11. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., Schlawe K., Chang H.D., Bopp T., Schmitt E., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5:e38.
12. Hoffmann P., Boeld T.J., Eder R., Huehn J., Floess S., Wieczorek G., Olek S., Dietmaier W., Andreesen R., Edinger M. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009, 39:1088-1097.
13. Wieczorek G., Asemissen A., Model F., Turbachova I., Floess S., Liebenberg V., Baron U., Stauch D., Kotsch K., Pratschke J., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009, 69:599-608.
14. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., Nakayama M., Rosenthal W., Bluestone J.A. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
15. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009, 106:1903-1908.
16. Long E., Wood K.J. Regulatory T cells in transplantation: transferring mouse studies to the clinic. Transplantation 2009, 88:1050-1056.
17. Kingsley C.I., Karim M., Bushell A.R., Wood K.J. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002, 168:1080-1086.
18. Oliveira V., Sawitzki B., Chapman S., Appelt C., Gebuhr I., Wieckiewicz J., Long E., Wood K.J. Anti-CD4-mediated selection of Treg in vitro-in vitro suppression does not predict in vivo capacity to prevent graft rejection. Eur J Immunol 2008, 38:1677-1688.
19. Feng G., Wood K.J., Bushell A. Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation 2008, 86:578-589.
20. Feng G., Gao W., Strom T.B., Oukka M., Francis R.S., Wood K.J., Bushell A. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 2008, 38:2512-2527.
21. Wei B., Baker S., Wieckiewicz J., Wood K.J. IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am J Transplant 2009, 10:69-80.
22. Carvalho-Gaspar M., Jones N.D., Luo S., Martin L., Brook M.O., Wood K.J. Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol 2008, 180:6640-6648.
23. Gao W., Lu Y., El Essawy B., Oukka M., Kuchroo V.K., Strom T.B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722-1732.
24. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
25. Raimondi G., Sumpter T.L., Matta B.M., Pillai M., Corbitt N., Vodovotz Y., Wang Z., Thomson A.W. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010, 184:624-636.
26. Joffre O., Santolaria T., Calise D., Al Saati T., Hudrisier D., Romagnoli P., van Meerwijk J.P. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008, 14:88-92.
27. Tsang J.Y., Tanriver Y., Jiang S., Xue S.A., Ratnasothy K., Chen D., Stauss H.J., Bucy R.P., Lombardi G., Lechler R. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008, 118:3619-3628.
28. Webster K.E., Walters S., Kohler R.E., Mrkvan T., Boyman O., Surh C.D., Grey S.T., Sprent J. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009, 206:751-760.
29. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St Groth B., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
30. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
31. Putnam A.L., Brusko T.M., Lee M.R., Liu W., Szot G.L., Ghosh T., Atkinson M.A., Bluestone J.A. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009, 58:652-662.
32. Nadig S.N., Wieckiewicz J., Wu D.C., Warnecke G., Zhang W., Luo S., Schiopu A., Taggart D.P., Wood K.J. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010, 16:809-813.
33. Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., Parizot C., Taflin C., Heike T., Valeyre D., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
34. Trzonkowski P., Bieniaszewska M., Juscinska J., Dobyszuk A., Krzystyniak A., Marek N., Mysliwska J., Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 2009, 133:22-26.
35. Peters J.H., Hilbrands L.B., Koenen H.J., Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS ONE 2008, 3:e2233.
36. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665.
37. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., Valmori D. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA 2009, 106:8635-8640.
38. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., Bover L., Hanabuchi S., Khalili J., Marinova E., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009, 106:4793-4798.
39. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., Hafler D.A. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113:4240-4249.
40. Wang R., Kozhaya L., Mercer F., Khaitan A., Fujii H., Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009, 106:13439-13444.
41. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
42. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., O'Shea J.J. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008, 111:1013-1020.
43. Lund J.M., Hsing L., Pham T.T., Rudensky A.Y. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008, 320:1220-1224.
44. Bushell A., Jones E., Gallimore A., Wood K. The generation of CD25+CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005, 174:3290-3297.
45. Carroll R.P., Segundo D.S., Hollowood K., Marafioti T., Clark T.G., Harden P.N., Wood K.J. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010, 21:713-722.
46. Vajdic C.M., McDonald S.P., McCredie M.R., van Leeuwen M.T., Stewart J.H., Law M., Chapman J.R., Webster A.C., Kaldor J.M., Grulich A.E. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.